BIOSIMILARS
| MOLECULE | MARKETED INDICATION | DEVELOPMENT | PRE-CLINICAL | CLINICAL |
|---|---|---|---|---|
| INSULIN REGULAR | TYPE I & TYPE II DIABETES | |||
| INSULIN GLARGINE | TYPE I & TYPE II DIABETES | |||
| BIPHASIC ISOPHANE INSULIN 30/70 | TYPE I & TYPE II DIABETES | |||
| LIRAGLUTIDE | TYPE II DIABETES | |||
| INSULIN ASPART | TYPE I & TYPE II DIABETES | |||
| TERIPARATIDE | OSTEOPOROSIS |
SMALL MOLECULES
| MOLECULE | MARKETED INDICATION |
|---|---|
| SODIUM HYALURONATE | OSTEOARTHRITIS |
| ENOXAPARIN | THROMBOPROPHYLAXIS |
Biphasic Isophane Insulin Injection IP
(r-DNA Origin)
Biphasic Isophane Insulin Injection BP 30/70
(r-DNA Origin)
Insulin Regular Injection IP
(r-DNA Origin)
Insulin Regular Injection IP
(r-DNA Origin)
Isophane Insulin Injection IP
(r-DNA Origin)
Insulin Injection, soluble (neutral) BP
(r-DNA Origin)
Insulin Glargine Injection BP
(r-DNA Origin)
Insulin Glargine Injection BP
(r-DNA Origin)
Copyright © Regenix Bioscience